Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Brainsway (BWAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

The consensus price target hints at a 32% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Brainsway (BWAY) Could Rally 32.01%: Here's is How to Trade

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?

Here's Why Momentum in Brainsway (BWAY) Should Keep going

Are Medical Stocks Lagging Brainsway (BWAY) This Year?

BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of its Deep Transcranial Magnetic Stimulation (Deep TMS™) platform in East Asia through the placement of 15 new systems in Taiwan and South Korea.

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

The consensus price target hints at a 34.4% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Brainsway (BWAY) Have the Potential to Rally 34.38% as Wall Street Analysts Expect?

Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable

Brainsway (BWAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Brainsway (BWAY) Soars 14.5%: Is Further Upside Left in the Stock?

Company to leverage capital and Valor's expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Brainsway (BWAY) is Your Friend, Here's Why

Byrna Technologies

Idaho Strategic Resources Inc

Limbach Holdings

Sezzle Inc

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BYRN, IDR, LMB, SEZL, BWAY.

5 Stocks With Recent Price Strength to Enhance Your Portfolio

BrainsWay Announces Significant Expansion on U.S. East Coast

BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the Israel Ministry of Defense's Rehabilitation Department has granted approval for the reimbursement of Deep Transcranial Magnetic Stimulation system (Deep TMS™) therapy for qualifying patients with post-traumatic stress disorder (PTSD) at Israeli public hospitals.

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

Great Lakes Dredge & Dock

Gorman-Rupp

360 Finance Inc - ADR

Let's take a look at four top-ranked stocks - BWAY, QFIN, GLDD and GRC - with impressive net profit margins for a robust portfolio.

4 Stocks Worth Adding to Your Portfolio on Solid Net Profit Margin

Does Brainsway Ltd. Sponsored ADR (BWAY) have what it takes to be a top stock pick for momentum investors?

Here's Why Brainsway Ltd. Sponsored ADR (BWAY) is a Great Momentum Stock to Buy

Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field

BrainsWay Appoints Richard A. Bermudes, M.D.

Fulcrum Therapeutics Inc

Heritage Insurance Hlds

Seanergy Maritime Hlds

Latham Group

Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay are included in this Analyst Blog.

The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay

We have narrowed our search to five small-cap stocks that have strong momentum. These are FULC, HRTG, SWIM, SHIP and BWAY.

5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts

The consensus price target hints at a 60.9% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 60.85% Upside in Brainsway (BWAY): Can the Stock Really Move This High?

Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?

BrainsWay reported strong earnings in Q2, with growth remaining strong and margins continuing to improve. Growth among enterprise accounts and internationally should ensure BrainsWay continues to perform well, provided that the macro environment remains stable. Neuronetics' decision to merge with Greenbrook TMS seems to support the strength of BrainsWay's business.

BrainsWay: Operating Leverage Driving Upside

Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Brainsway (BWAY) Might be Well Poised for a Surge

News for Brainsway Stock (BWAY)